LIFECORE BIOMEDICAL, INC. Receivable with Imputed Interest, Effective Yield (Interest Rate)
LIFECORE BIOMEDICAL, INC. (LFCR) reported Receivable with Imputed Interest, Effective Yield (Interest Rate) of 8.50% for the 12-month period ending 2025-05-25, per its 10-K filed 2025-08-07.
Financial Statements › Notes › and Others
us-gaap:ReceivableWithImputedInterestEffectiveYieldInterestRate · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. receivable with imputed interest, effective yield (interest rate) for fiscal 2025 was 8.50%.
| Period end | Receivable with Imputed Interest, Effective Yield (Interest Rate) | Receivable with Imputed Interest, Effective Yield (Interest Rate) 9 month | Receivable with Imputed Interest, Effective Yield (Interest Rate) 12 month |
|---|---|---|---|
| 2025-05-25 | 8.50% 10-KT · filed 2026-03-16 | 8.50% 10-K · filed 2025-08-07 | |
| 2025-02-23 | 8.50% 10-Q · filed 2025-11-06 | 8.50% 10-Q · filed 2025-04-03 | |
| 2025-01-07 | 8.50% 10-Q · filed 2026-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |